How Albuminuria, Molecular Medicine and Lifestyle are Reshaping Kidney Disease

Recent key publications 

Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis. 
Br J Cancer 2025; 133:1535-1543 Mok Y, Surapaneni A, Sang Yet al.

Link to full article: https://pubmed.ncbi.nlm.nih.gov/40914744/

The growing recognition of albuminuria as a clinically actionable biomarker, underscored by its formal incorporation into the KDIGO 2024 CKD classification framework, makes the study by Mok and colleagues particularly timely. Drawing on over 1.3 million participants across 54 international cohorts from the CKD Prognosis Consortium, this rigorous individual participant data meta-analysis demonstrates that elevated urinary albumin-to-creatinine ratio is independently associated with increased overall cancer risk (adjusted HR 1.08 per 8-fold increase), whereas eGFR shows no consistent association with overall cancer incidence. Overall cancer risk rose progressively with increasing UACR category, reaching a 26% increase at UACR exceeding 300 mg/g. The large number of implicated malignancies include lung, colorectal, liver and haematolymphoid cancers, and raise compelling mechanistic questions as well as positioning albuminuria as a candidate biomarker for cancer risk stratification well beyond its established cardiovascular and renal prognostic role.

Modelling heterogeneity in the progression of chronic kidney disease. 
Nephrol Dial Transplant 2025; 40:1107-1114 Butz E, Schultheiss UT, Sekula P.

Link to full article:https://pubmed.ncbi.nlm.nih.gov/39701823/

As longitudinal cohort data in chronic kidney disease (CKD) research continue to accumulate, the limitations of conventional time-to-first-event analyses become harder to ignore. This review makes a compelling case for moving beyond that framework, drawing on disease trajectory mapping and recurrent event modelling as tools better suited to the clinical reality of CKD; a condition defined not by a single endpoint, but by a shifting, heterogeneous course. The German Chronic Kidney Disease study serves as a practical illustration of how these methods uncover variation in disease progression and quantify the cumulative burden of recurrent episodes such as acute kidney injury; information that standard approaches routinely obscure. At a moment when precision medicine and multimorbidity research are reshaping expectations for clinical data, this methodological contribution offers something genuinely useful: a more honest accounting of what longitudinal cohorts already contain and a clearer path toward analyses that can inform individualised patient management.

Extrarenal manifestations in inherited kidney diseases. 
Nephrol Dial Transplant 2025; 40: 227-233 Hoefele J, Eble J, Hermle T et al.

Link to full article:https://pubmed.ncbi.nlm.nih.gov/39096159/

Inherited kidney diseases effects far more organ systems than their name suggests, yet extrarenal manifestations remain poorly recognised in both clinical practice and research literature. This review addresses that gap directly, summarising current knowledge across a broad range of disease categories, from ciliopathies to mitochondrial disorders, and drawing on OMIM data to produce a structured, multisystem overview that is long overdue. As genomic diagnostics move steadily into routine nephrology practice, the ability to recognise these patterns across organ boundaries becomes not just academically interesting but clinically necessary for coordinated, interdisciplinary care. Recent therapeutic developments underline that urgency considerably: RNA-based interventions for primary hyperoxaluria now offer an example of how precise molecular understanding translates into clinical benefit. The comprehensive table accompanying this review deserves particular attention; it functions as a practical reference tool that clinicians and researchers can return to in clinically challenging situations.

Blood DNA methylation markers are associated with diabetic kidney disease progression in type 1 diabetes. 
Diabetologia 2026; Syreeni A, Dahlström EH, Smyth LJet al.

Link to full article:https://pubmed.ncbi.nlm.nih.gov/41569424/ 

Identifying patients with type 1 diabetes who will progress to end-stage kidney disease remains one of the more stubborn clinical challenges in nephrology, and epigenetic markers may finally offer a way forward. This prospective epigenome wide association study reports 11 DNA methylation loci associated with diabetic kidney disease progression, among them a novel early-stage signal at the podocyte specific CDKN1C locus; a finding that points toward disease mechanisms operating well before conventional clinical markers become informative. By integrating genetic and proteomic data alongside methylation profiles, the authors show that these markers improve risk prediction beyond what standard clinical variables alone can achieve. That incremental gain in predictive accuracy is not trivial; in a disease where early intervention windows are narrow, better stratification tools carry real consequences for patient outcomes. Set against the current momentum in epigenetic biomarker development and the broader push toward precision nephrology, this work builds a credible case for methylation-based approaches as a serious framework for identifying patients most in need of intensified surveillance or early therapeutic escalation.

The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney Int 2026; 109:442-464 Furth SL, Colhoun HM, Kanbay Met al.

Link to full article:https://pubmed.ncbi.nlm.nih.gov/41176308/

Managing patients with both obesity and chronic kidney disease (CKD) has never been straightforward and this KDIGO Controversies Conference report captures why. Working through epidemiology, pathophysiology and treatment in a logical progression, the report delivers something clinical guidance in this area has often lacked: specificity. BMI gets the critical reassessment it deserves, with the authors laying out in concrete terms why it falls short as a measure of adiposity in CKD populations. The evaluation of incretin-based therapies is equally grounded, moving beyond general enthusiasm to examine what trials like FLOW and SELECT actually demonstrated about kidney protection. Metabolic surgery receives comparable scrutiny, with the analysis extending well past weight loss metrics to consider the broader physiological consequences that make it relevant to CKD management specifically. What makes this report worth reading is that it does not stop at summarising what is known. It translates complex evidence base into a framework that can guide real clinical decisions for patients whose metabolic and kidney disease are not separate problems but expressions of shared biological processes. As obesity rates continue to rise globally and precision approaches to metabolic disease gain ground, this structured review will serve both practicing clinicians and researchers working at the nephrology and metabolism interface.

Emerging Cardiovascular Risk Factors in Chronic Kidney Disease in the "Omics" Era: Gut and Beyond. 
Mayo Clin Proc 2026; Sumida K, Kovesdy CP.

Link to full article:https://pubmed.ncbi.nlm.nih.gov/41686097/

Understanding why cardiovascular risk in chronic kidney disease (CKD) remains so difficult to predict and manage may require looking beyond conventional clinical markers, and this review makes a persuasive argument that multiomics approaches are where the most informative answers are likely to emerge. Microbiomics, proteomics, metabolomics, transcriptomics, epigenomics and genomics: the synthesis maps a rapidly expanding landscape of molecular candidates with genuine mechanistic and predictive relevance. Several stand out: circulating microbial signatures, the protein SPARCL1, gut derived metabolites, microRNAs, DNA methylation patterns and clonal haematopoiesis of indeterminate potential each represent a line of evidence that complicates, and ultimately enriches, the standard clinical picture of CKD related cardiovascular disease. What makes this review worth reading closely is not simply the breadth of its coverage but its clear vision of where the field stands. The path from molecular discovery to clinical utility in risk stratification and therapeutic targeting remains challenging and the authors do not disregard that gap. As integrated multiomics analyses and causal inference methods become more tractable, the conceptual framework laid out in this publication will serve as a useful orientation for investigators and clinicians trying to determine which findings are ready to act on and which still require deeper validation.

The global epidemiology of acute kidney injury: challenges and opportunities. 
Nat Rev Nephrol 2026; 22:179-198 Cerda J, Kashani K, Ostermann Met al.

Link to full article:https://pubmed.ncbi.nlm.nih.gov/41350436/

Acute kidney injury (AKI) causes death at a scale that global health policy has yet to adequately acknowledge. The gap in how AKI is recognised and managed between well-resourced and low-resource settings remains among the most consequential disparities in nephrology today. This review takes that problem seriously, drawing on data from the Global Kidney Health Atlas and the foundational work of the I.S.N. 0-by-25 initiative to chart the epidemiological burden across a broad range of aetiologies, including sepsis, COVID 19, pregnancy related AKI and tropical infections. The 5R framework covering risk, recognition, response, renal support and rehabilitation provide the clinical discussion with a coherent structure that holds up across diverse care contexts without reducing genuinely difficult problems to tidy categories. The review's most valuable contribution, however, may be its willingness to engage with forces that are actively reshaping AKI burden but have not yet received proportionate attention in the nephrology literature. Climate change is driving shifts in the frequency and severity of heat related illness, infectious disease and food insecurity, all of which carry direct implications for kidney health. At the same time, structural inequities continue to govern who receives a timely diagnosis and who does not. Digital health tools and biomarker guided approaches are presented here not as distant possibilities but as strategies with realistic near-term implementation potential across diverse settings. Researchers and clinicians engaged with AKI at any stage of the care pathway will find the priorities outlined in this review both timely and actionable.